sibutramine has been researched along with Lipidoses in 1 studies
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride
Lipidoses: Conditions characterized by abnormal lipid deposition due to disturbance in lipid metabolism, such as hereditary diseases involving lysosomal enzymes required for lipid breakdown. They are classified either by the enzyme defect or by the type of lipid involved.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Chronic administration of BI 186908 resulted in significant body weight reduction comparable to sibutramine in a 4 week diet-induced obesity model in rats." | 3.81 | Design, synthesis and evaluation of MCH receptor 1 antagonists--Part III: Discovery of pre-clinical development candidate BI 186908. ( Arndt, K; Budzinski, R; Heckel, A; Kley, JT; Lehmann, T; Lenter, M; Lotz, RR; Maier, GM; Markert, M; Müller, S; Oost, T; Roth, GJ; Rudolf, K; Stenkamp, D; Thomas, L, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oost, T | 1 |
| Heckel, A | 1 |
| Kley, JT | 1 |
| Lehmann, T | 1 |
| Müller, S | 1 |
| Roth, GJ | 1 |
| Rudolf, K | 1 |
| Arndt, K | 1 |
| Budzinski, R | 1 |
| Lenter, M | 1 |
| Lotz, RR | 1 |
| Maier, GM | 1 |
| Markert, M | 1 |
| Thomas, L | 1 |
| Stenkamp, D | 1 |
1 other study available for sibutramine and Lipidoses
| Article | Year |
|---|---|
Design, synthesis and evaluation of MCH receptor 1 antagonists--Part III: Discovery of pre-clinical development candidate BI 186908.
Topics: Animals; Anti-Obesity Agents; Appetite Depressants; Body Weight; Cyclobutanes; Drug Discovery; Ether | 2015 |